Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

COVAX allocates 4.7 mln AstraZeneca COVID-19 vaccine doses to N.Korea

11/30/2021 | 03:08am EST

SEOUL, Nov 30 (Reuters) - The global vaccine-sharing network COVAX has set aside 4.73 million doses of AstraZeneca Plc's COVID-19 shot for shipment to North Korea, one of the very few countries that haven't started vaccination, according to its allocation plan.

The plan follows an earlier offer for nearly two million doses of the shot that the reclusive state had rejected due to concerns over side effects, according to a South Korean think-tank.

South Korea's unification ministry which oversees engagement with the North said on Tuesday it appears detailed distribution arrangement has yet to be made, as COVAX continues to engage with Pyongyang.

The allocation is part of its plan to distribute 43 million doses of the AstraZeneca vaccine and Moderna's COVID-19 shot by the end of December, as COVAX aims to ship up to 1 billion doses in total this year.

Co-led by the World Health Organization (WHO), COVAX https://www.reuters.com/business/healthcare-pharmaceuticals/first-covax-send-covid-shots-only-least-covered-nations-2021-10-01 has since January largely allocated vaccine doses proportionally among its 140-plus beneficiary states according to population size.

North Korea and Eritrea are the only countries that have yet to start their vaccination campaign against CCOVID-19, according to the WHO.

North Korea has not officially confirmed any COVID-19 cases, a position questioned by South Korean and U.S. officials. But it has imposed strict anti-virus measures, including border closures and domestic travel curbs.

North Korean leader Kim Jong Un had said in June that the failure to implement measures to tackle the coronavirus had caused a "great crisis https://www.reuters.com/world/asia-pacific/north-koreas-kim-chides-officials-unspecified-pandemic-lapse-2021-06-29, " according to state media.

By Nov. 11 North Korea had tested at least 45,564 people for COVID-19 with no positive results, according to the WHO https://cdn.who.int/media/docs/default-source/searo/whe/coronavirus19/sear-weekly-reports/searo-weekly-situation-report-45-2021-.pdf?sfvrsn=de09f032_5. (Reporting by Sangmi Cha; Editing by Miyoung Kim and Raissa Kasolowsky)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 2.65% 8770 Delayed Quote.-1.54%
MODERNA, INC. -2.59% 204.73 Delayed Quote.-19.39%
All news about ASTRAZENECA PLC
04:37aEnhertu granted Priority Review in the US for patients with HER2-positive metastatic br..
AQ
03:01aCline Scientific extends collaboration agreement with AstraZeneca
AQ
02:40aAstraZeneca's Enhertu Granted Priority Review by US Regulator
DJ
02:31aJens Lindberg takes office as CEO of Medivir on January 24
AQ
02:23aAstraZeneca-Daiichi Sankyo's Breast Cancer Drug Accepted For Priority Review in US
MT
02:06aProsecution Takes Over Case of 8 Medics Pinned for Misusing Covid-19 Vaccines
AQ
01:09aIsrael Reopens Borders To Entry By Foreign Nationals
AQ
01/14EMA lists rare spinal condition as side effect of AstraZeneca's COVID-19 shot
RE
01/14European Medicines Agency Asks AstraZeneca, Johnson & Johnson To Add Spinal Inflammatio..
MT
01/14EMA Recommends To Include Transverse Myelitis As Side Effect Of Vaxzevria and COVID-19 ..
RE
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 079 M - -
Net income 2021 2 716 M - -
Net Debt 2021 24 814 M - -
P/E ratio 2021 53,4x
Yield 2021 2,40%
Capitalization 186 B 186 B -
EV / Sales 2021 5,84x
EV / Sales 2022 4,79x
Nbr of Employees 76 100
Free-Float -
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 116,82 $
Average target price 138,50 $
Spread / Average Target 18,6%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC-1.54%181 019
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317